SEC EDGARJUL 171 min read$JBL

Schick Gary K. sold $320K of JBL

Schick Gary K. (SVP, CHRO) sold 1,000 shares of JABIL INC (JBL) at an average of $319.86 ($315.05–$330.00, $0.32M total) across 9 trades on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Schick Gary K.

Published Jul 17, 2026, 12:27 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 17, 2026, 12:35 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$JBL

Neutral

high confidence

Mentioned

$JBL

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$JBLNeutralLow

Why it matters

The only new information is the insider sale details (size, dates, price range, and 10b5-1 usage). No new company fundamentals are provided.

Market read

Traders may note the insider selling for sentiment/positioning, but it is unlikely to drive a fundamental repricing without additional catalysts.

What to watch

The transaction is spread across multiple trades and executed under a pre-arranged plan, reducing interpretability versus discretionary selling.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-17 after the 2026-07-15 sale execution window.

Background

The article is an SEC Form 4 insider transaction disclosure for Jabil (JBL) by its CHRO, Schick Gary K.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JBLNeutralHigh confidence

Context

Jabil insider Schick Gary K., SVP and CHRO, sold about $319.9K of JBL shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying company-specific news or guidance changes.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity without disclosed business developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales often reflect scheduled liquidity needs rather than bearish expectations, so the signal may be overstated.

Key entities

issuer
Jabil Inc
Subject of the Form 4 insider transaction disclosure.
insider
Schick Gary K.
SVP and CHRO who sold shares under a 10b5-1 plan.

Read at source ← All news

SEP 25

$AKAMHighAI 9/10

Anthropic signs US$11.6 billion cloud deal with Akamai, gets warrant for up to 5% stake

Anthropic agreed to a US$11.6 billion cloud services deal with Akamai, including a warrant for up to 5% stake. Akamai shares rose 20% in extended trading. The 7-year contract involves purchasing Series B shares at US$111.33 each, converting to 7.7 million common shares. Akamai expects US$5.5 billion in capital expenditure and US$1.7 billion increase in 2026 spending.

businesstimes.com.sg2 min

SEP 14

$JBLMed

Why Jabil (JBL) Shares Are Plunging Today

Jabil (JBL) shares fell 5.1% after Goldman Sachs lowered its price target to $375, citing a more cautious valuation. The stock is volatile, down 22% from its 52-week high, but up 25.1% year-to-date. Higher bond yields and oil prices pose risks for the company.

financialcontent.com2 min

SEP 11

$JBLMed

JBL Stock Rises as Goldman Sachs Backs AI Growth Story

Jabil Inc. (JBL) stock rose 5.65% after strong earnings guidance. Goldman Sachs, while cutting its target to $375, expects 50% AI revenue growth and 6% EBIT margins. JBL reported $8.75B revenue, $275M net income, and 3% profit margin. The stock is in an uptrend, with support at $300 and resistance around $340.

stockstotrade.com2 min

SEP 7

$JBLMedAI 8/10

Jabil Rises 36.2% Year to Date: Should You Buy the Stock?

Jabil Inc. (JBL) has risen 36.2% year-to-date, outperforming its industry and the S&P 500. The company expects AI-related revenues to reach $13.6B in fiscal 2026, up from $9B in 2025, and is expanding manufacturing capacity to meet demand. JBL also sees growth in healthcare, renewable energy, and digital commerce sectors, but faces supply chain and competition challenges.

finance.yahoo.com2 min

SEP 4

$JBLHighAI 8/10

FDA Contamination Warning Could Be A Game Changer For Jabil’s (JBL) Pharma Ambitions

The FDA issued a warning to Jabil's Pharmaceutics International facility, citing significant violations of sterile drug manufacturing practices, including fungal contamination and weak quality oversight. This raises concerns about Jabil's ability to manufacture sterile products and could impact its pharmaceutical expansion plans. Jabil's 2026 revenue guidance of $35 billion includes contributions from healthcare and pharma, which may now be questioned by investors.

simplywall.st3 min

AUG 20